Govt has no plans to control medical devices sector

Govt wants to allow market forces to decide prices of medical devices but asked industry not to extract very high margins

<a href="http://www.shutterstock.com/pic-228848833/stock-photo-pills-drug.html" target="_blank">Image</a> via Shutterstock
Ajay Modi New Delhi
Last Updated : Aug 29 2015 | 1:08 AM IST
The government has no plans to control prices of medical devices even as it continues to expand price regulation in drugs. The government wants players in the medical devices industry to follow self-regulation and refrain from charging unseasonably high margins.

“Pricing policy is bothering both the pharmaceuticals and medical devices industries. The medical devices sector is at its infancy. Let it become a $50 billion industry. There is no need for any apprehension at this stage,” said V K Subburaj, secretary, department of pharmaceuticals. There is, however, no plan to ease the controls on pricing of drugs. Subburaj said the government wanted to allow market forces to decide prices of medical devices but asked the industry not to extract very high margins. “Many products are imported cheap and sold at ten times the price. High margins attract attention. Wherever prices are high, the industry should make it reasonable,” he said.

The government recently made the department of pharmaceuticals the nodal body for the medical devices industry. Regulatory issues will, however, continue to fall under the ministry of health, and exports and imports will be governed by the commerce ministry. The domestic medical devices market is estimated at $6.8 billion, but only one-third of it is locally manufactured. India also exports medical devices worth nearly $1 billion. Referring to the anomalies in the tax structure that act against local manufacturing of medical equipment, Subburaj said the issue was being examined at the highest level. “We hope to correct these anomalies well in time to create an ecosystem for local manufacturing,” he added.

A CII-BCG report, Medical Technology: Vision 2025, released today said several companies like GE, Polymed, BD and Terumo Penpol had ramped up investments in India and were seeing strong business results. However, for further growth, the government needs to spend more on healthcare, introduce single window regulation for manufacturing of medical devices, and provide incentives such as tax holidays and soft loans.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 29 2015 | 12:36 AM IST

Next Story